SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jenburkt Pharma - Quaterly Results

06 Feb 2024 Evaluate
A minor change in the total revenue was seen in the December 2023 quarter. The total revenue for the quarter stood at Rs. 356.60 millions against Rs. 345.66 millions during year ago period.The Net proft of the company remain more or less same to Rs. 54.03  millions from Rs. 54.34 millions ,decline by -0.57%.Operating profit for the quarter ended December 2023 rose to 85.39 millions as compared to 84.44 millions of corresponding quarter ended December 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 356.60 345.66 3.16 1031.24 1015.50 1.55 1367.49 1239.80 10.30
Other Income 13.46 14.64 -8.06 34.79 38.68 -10.06 51.23 49.49 3.52
PBIDT 85.39 84.44 1.13 267.44 267.37 0.03 354.90 322.04 10.20
Interest 0.70 1.03 -32.04 2.13 2.84 -25.00 3.67 4.35 -15.63
PBDT 84.69 83.41 1.53 265.31 264.53 0.29 351.23 317.69 10.56
Depreciation 6.30 5.84 7.88 17.21 16.64 3.43 22.59 18.99 18.96
PBT 78.39 77.57 1.06 248.10 247.89 0.08 328.64 298.70 10.02
TAX 24.36 23.23 4.86 67.15 65.36 2.74 82.58 75.74 9.03
Deferred Tax -0.64 -1.77 -63.84 -3.53 -3.87 -8.79 -2.25 2.96 -176.01
PAT 54.03 54.34 -0.57 180.95 182.53 -0.87 246.06 222.96 10.36
Equity 44.13 45.66 -3.35 44.13 45.89 -3.84 44.13 45.89 -3.84
PBIDTM(%) 23.95 24.43 -1.98 25.93 26.33 -1.50 25.95 25.98 -0.09

Jenburkt Pharma Share Price

1050.40 24.80 (2.42%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×